George D Demetri

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
    George D Demetri
    Ludwig Center at Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    Lancet 381:295-302. 2013
  2. ncbi Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure
    George D Demetri
    Center for Sarcoma and Bone Oncology, Ludwig Center at Dana Farber Harvard Cancer Center, Dana Farber Cancer Institute, 450 Brookline Ave, Dana 1212, Boston, MA 02215, USA
    Clin Cancer Res 18:3170-9. 2012
  3. ncbi First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study
    George D Demetri
    Harvard Cancer Center, Boston, MA, USA
    Eur J Cancer 48:547-63. 2012
  4. ncbi A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors
    George D Demetri
    Ludwig Center at Dana Farber Harvard Cancer Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 15:5910-6. 2009
  5. ncbi Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure
    George D Demetri
    Center for Sarcoma and Bone Oncology, Ludwig Center at Dana Farber Harvard Cancer Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 15:5902-9. 2009
  6. ncbi Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors
    George D Demetri
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Semin Oncol 38:S10-9. 2011
  7. ncbi Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development
    George D Demetri
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, 44 Binney Street Southwest, Boston, MA 02115, USA
    Hematol Oncol Clin North Am 16:1115-24. 2002
  8. ncbi Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
    George D Demetri
    Ludwig Center at Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Lancet 368:1329-38. 2006
  9. ncbi Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571)
    George D Demetri
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Eur J Cancer 38:S52-9. 2002
  10. ncbi Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas
    Sant P Chawla
    International Institute of Clinical Studies, Sarcoma Oncology Center, Santa Monica, CA, USA
    J Clin Oncol 30:78-84. 2012

Detail Information

Publications104 found, 100 shown here

  1. ncbi Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
    George D Demetri
    Ludwig Center at Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    Lancet 381:295-302. 2013
    ..We aimed to assess efficacy and safety of regorafenib in patients with metastatic or unresectable GIST progressing after failure of at least imatinib and sunitinib...
  2. ncbi Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure
    George D Demetri
    Center for Sarcoma and Bone Oncology, Ludwig Center at Dana Farber Harvard Cancer Center, Dana Farber Cancer Institute, 450 Brookline Ave, Dana 1212, Boston, MA 02215, USA
    Clin Cancer Res 18:3170-9. 2012
    ....
  3. ncbi First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study
    George D Demetri
    Harvard Cancer Center, Boston, MA, USA
    Eur J Cancer 48:547-63. 2012
    ..This study evaluated the safety and efficacy of doxorubicin ± conatumumab as first-line systemic therapy for metastatic or locally advanced/unresectable soft-tissue sarcoma...
  4. ncbi A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors
    George D Demetri
    Ludwig Center at Dana Farber Harvard Cancer Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 15:5910-6. 2009
    ..To study the safety, tolerability, and pharmacokinetics of the selective tyrosine kinase inhibitor nilotinib as a single agent or in combination with imatinib in patients with advanced imatinib-resistant gastrointestinal stromal tumors...
  5. ncbi Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure
    George D Demetri
    Center for Sarcoma and Bone Oncology, Ludwig Center at Dana Farber Harvard Cancer Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 15:5902-9. 2009
    ....
  6. ncbi Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors
    George D Demetri
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Semin Oncol 38:S10-9. 2011
    ..In addition, the ability of some TKIs to inhibit alternative targets with potency similar to or greater than their intended primary target (pleiotropic effects) is also discussed...
  7. ncbi Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development
    George D Demetri
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, 44 Binney Street Southwest, Boston, MA 02115, USA
    Hematol Oncol Clin North Am 16:1115-24. 2002
    ..Integration of signal transduction inhibitors into the armamentarium of cancer therapeutics will undoubtedly continue based on this important paradigm of GIST...
  8. ncbi Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
    George D Demetri
    Ludwig Center at Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Lancet 368:1329-38. 2006
    ....
  9. ncbi Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571)
    George D Demetri
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Eur J Cancer 38:S52-9. 2002
    ..This work provides proof of concept to the hypothesis that selective inhibition of aberrant signal transduction can provide important anticancer activity, if the proper signaling pathways are identified and blocked...
  10. ncbi Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas
    Sant P Chawla
    International Institute of Clinical Studies, Sarcoma Oncology Center, Santa Monica, CA, USA
    J Clin Oncol 30:78-84. 2012
    ..This multicenter, open-label, single-arm, phase II trial was conducted to assess the antitumor activity of ridaforolimus in patients with distinct subtypes of advanced sarcomas...
  11. ncbi Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors
    George D Demetri
    Ludwig Center, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 15:6232-40. 2009
    ..To determine the maximum tolerated dose, dose-limiting toxicity (DLT), and recommended phase II dose of dasatinib in metastatic solid tumors refractory to standard therapies or for which no effective standard therapy exists...
  12. ncbi Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules
    George D Demetri
    Center for Sarcoma and Bone Oncology and Ludwig Center of Dana Farber Harvard Cancer Center, Dana Farber Cancer Institute, D1212 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 27:4188-96. 2009
    ....
  13. ncbi Structural reengineering of imatinib to decrease cardiac risk in cancer therapy
    George D Demetri
    Ludwig Center for Cancer Research, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Clin Invest 117:3650-3. 2007
    ..The study shows that structural reengineering of a kinase-inhibitory drug to improve tolerability while preserving efficacy is feasible...
  14. ncbi ET-743: the US experience in sarcomas of soft tissues
    George D Demetri
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Anticancer Drugs 13:S7-9. 2002
    ..There were no treatment-associated deaths. In conclusion, ET-743 is an active chemotherapeutic agent that can induce objective responses and clinical benefit in a subset of patients with metastatic or advanced soft-tissue sarcoma...
  15. ncbi Targeted approaches for the treatment of thrombocytopenia
    G D Demetri
    Dana Farber Cancer Institute, Boston, Massachusetts 02115 6084, USA
    Oncologist 6:15-23. 2001
    ..As a potent stimulator of platelet production, rHuTPO has the potential to reduce the need for platelet transfusions and their attendant complications...
  16. ncbi Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy
    George D Demetri
    Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Clin Breast Cancer 3:45-51. 2002
    ..3 times weekly). Epoetin alfa is, therefore, effective and safe in the management of anemia in patients with breast cancer treated with chemotherapy...
  17. ncbi Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy
    R Garcia-Carbonero
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, Harvard Medical School, Shields Warren Bldg, Room G530, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 22:1480-90. 2004
    ....
  18. ncbi Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors
    George D Demetri
    Ludwig Center, Dana Farber Harvard Cancer Center, Dana Farber Cancer Institute, D1212, 44 Binney St, Boston MA 02115, USA
    J Clin Oncol 27:3141-7. 2009
    ..Patients with IM C(min) below 1,100 ng/mL showed a shorter TTP and lower rate of clinical benefit (OOBR). Further studies are justified to test whether monitoring IM plasma levels might optimize clinical outcomes for patients with GIST...
  19. ncbi Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial
    Suzanne George
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute D1212, 450 Brookline Ave, Boston, MA, USA
    J Clin Oncol 30:2401-7. 2012
    ....
  20. ncbi Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib
    Katherine A Janeway
    Pediatric Oncology, Dana Farber Cancer Institute and Department of Medicine, Children s Hospital Boston, Boston, Massachusetts 02115, USA
    Pediatr Blood Cancer 52:767-71. 2009
    ..Sunitinib prolongs survival in adult patients with imatinib-resistant gastrointestinal stromal tumor (GIST). We report the experience with sunitinib in pediatric patients with advanced GIST following failure of imatinib...
  21. ncbi Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors
    Jayesh Desai
    Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 13:5398-405. 2007
    ..The objective of this study was to correlate molecular and radiologic patterns of imitinib-refractory disease with existing conventional criteria for disease progression...
  22. ncbi Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors
    Chandrajit P Raut
    Department of Surgery, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 24:2325-31. 2006
    ..Surgery has little to offer in the setting of generalized progression...
  23. ncbi NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors
    George D Demetri
    Ludwig Center at Dana Farber Harvard Cancer Center, USA
    J Natl Compr Canc Netw 8:S1-41; quiz S42-4. 2010
    ..The task force met for the first time in October 2003 and again in December 2006 and October 2009. This supplement describes the recent developments in the field of GIST as discussed at the October 2009 meeting...
  24. ncbi Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate
    Chandrajit P Raut
    Department of Surgery, Brigham and Women s Hospital, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA
    Ann Surg Oncol 17:407-15. 2010
    ..Impact of surgery in IM-resistant patients on second-line sunitinib (SU) is unknown...
  25. ncbi Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas
    Suzanne George
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, 44 Binney St, D1210, Boston, MA 02115, USA
    J Clin Oncol 27:3154-60. 2009
    ....
  26. ncbi Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs)
    Anette Duensing
    Department of Pathology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Cancer Res 64:5127-31. 2004
    ..PKCtheta is strongly activated in most GISTs and hence may serve, along with KIT/PDGFRA, as a novel therapeutic target...
  27. ncbi Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas
    John V Heymach
    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
    Clin Cancer Res 10:5732-40. 2004
    ..Correlative studies suggest that VEGF receptor or KIT inhibition was incomplete in at least some cases, providing a possible explanation for the observed lack of activity...
  28. ncbi Imatinib targeting of KIT-mutant oncoprotein in melanoma
    Xiaofeng Jiang
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Clin Cancer Res 14:7726-32. 2008
    ..Biological effects of KIT inhibition in these melanomas remain poorly understood. We sought to investigate further the effects of imatinib in these melanoma subsets...
  29. ncbi Imaging features of bone metastases in patients with gastrointestinal stromal tumors
    Anupma Jati
    Department of Radiology, Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Diagn Interv Radiol 18:391-6. 2012
    ..To determine the prevalence and imaging features of bone metastases in patients with gastrointestinal stromal tumors (GISTs)...
  30. ncbi Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours
    Suzanne George
    Dana Farber Cancer Institute, Massachusetts General Hospital, Ludwig Center for Cancer Research at Dana Farber Harvard, Harvard Medical School, Boston, MA, USA
    Eur J Cancer 42:864-70. 2006
    ..It remains unclear whether addition of growth factors might improve tolerability for imatininb in combination with cytotoxic chemotherapy...
  31. ncbi A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors
    David P Ryan
    Division of Hematology Oncology, Massachusetts General Hospital, Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
    Oncologist 7:531-8. 2002
    ..To assess the efficacy, tolerability, and pharmacokinetics of ecteinascidin 743 (ET-743) in patients with advanced gastrointestinal stromal tumors (GISTs)...
  32. ncbi Multimodality treatment of mesenteric desmoid tumours
    Monica M Bertagnolli
    Department of Surgery, Brigham and Women s Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Eur J Cancer 44:2404-10. 2008
    ..When desmoids arise in the intestinal mesentery, surgical resection is seldom possible without life-altering loss of intestinal function...
  33. ncbi Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 32-2004. A 68-year-old man with a large retroperitoneal mass
    George D Demetri
    Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, USA
    N Engl J Med 351:1779-87. 2004
  34. ncbi Leiomyosarcoma of the inferior vena cava: survival after aggressive management
    Hiromichi Ito
    Department of Surgery, Brigham and Women s Hospital, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA
    Ann Surg Oncol 14:3534-41. 2007
    ..Leiomyosarcoma (LMS) of the inferior vena cava (IVC) is exceedingly rare. The role of adjuvant therapy remains undefined. This study evaluated outcomes after aggressive management...
  35. ncbi Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial
    Palma Dileo
    Department of Medical Oncology, Center for Sarcoma and Bone Oncology and Ludwig Center for Cancer Research, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 109:1863-9. 2007
    ..This study evaluated the efficacy and tolerability of gemcitabine plus vinorelbine in advanced soft-tissue sarcoma...
  36. ncbi Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma
    Chandrajit P Raut
    Department of Surgery, Brigham and Women s Hospital, Dana Farber Cancer Institute, Harvard Medical School, 75 Francis Street, Boston, MA 02115, United States
    Eur J Cancer 45:2818-24. 2009
    ..Neither has been validated in ULMS. We critically evaluated both systems to determine if either identified patient groups with distinct outcomes...
  37. ncbi Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
    George D Demetri
    Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA 02115, USA
    N Engl J Med 347:472-80. 2002
    ..Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy...
  38. ncbi Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors
    Samuel Singer
    Department of Pathology and Surgery, Brigham and Women s Hospital, Boston, MA, USA
    J Clin Oncol 20:3898-905. 2002
    ..The aim of this study was to evaluate the prognostic relevance for KIT mutations in a series of GISTs in which the mutations were evaluated intensively by genomic and cDNA sequencing...
  39. ncbi Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors
    Richard Quek
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 17:871-9. 2011
    ..Pharmacokinetics and preliminary antitumor effects of the combination were evaluated...
  40. ncbi Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors
    Jayesh Desai
    Brigham and Women's Hospital, Dana Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts 02115, USA
    Ann Intern Med 145:660-4. 2006
    ..This provides a rationale for further investigation of sunitinib treatment in patients with advanced thyroid cancer...
  41. ncbi Current management of metastatic gastrointestinal stromal tumor: a case report
    Suzanne George
    Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
    Clin Adv Hematol Oncol 1:63-4; discussion 65. 2003
  42. ncbi Major response to imatinib mesylate in KIT-mutated melanoma
    F Stephen Hodi
    The Melanoma Program, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 26:2046-51. 2008
  43. ncbi A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer
    Matthew H Kulke
    Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer J 8:395-9. 2002
    ..The median progression-free survival time was only 1.6 months, and the median survival time was 3.9 months. DISCUSSION: Troglitazone is not an active agent for the treatment of metastatic colorectal cancer...
  44. ncbi Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors
    Andrew J Wagner
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 28:835-40. 2010
    ..The clinical activity of sirolimus in PEComa additionally strengthens the pathobiologic similarities linking PEComas to other neoplasms related to the tuberous sclerosis complex...
  45. ncbi Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948)
    Chandrajit P Raut
    Department of Surgery, Brigham and Women s Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 7:e26331. 2012
    ....
  46. ncbi Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity
    Thomas A Puchalski
    Dana-Farber/Partners Cancer Care, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Chemother Pharmacol 50:309-19. 2002
    ..Optimizing dosing strategies to further enhance the therapeutic index of ET-743 may depend upon obtaining a better understanding of the metabolic fate of the drug in humans...
  47. ncbi Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred
    Frederick P Li
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 23:2735-43. 2005
    ..A tumor from the proband was analyzed to compare features with sporadic GISTs...
  48. ncbi Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study
    Harold J Burstein
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Breast Cancer Res Treat 79:391-7. 2003
    ..To evaluate the therapeutic effects of the peroxisome proliferator-activated receptor (PPAR) gamma activating ligand, troglitazone, in patients with refractory metastatic breast cancer...
  49. ncbi Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor
    Sebastian Bauer
    Department of Pathology, Brigham and Women's Hospital, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, and Ludwig Center at Dana Farber/Harvard Cancer Center, Boston, Massachusetts 02115, USA
    Cancer Res 66:9153-61. 2006
    ..The dramatic inactivation of imatinib-resistant KIT oncoproteins suggests that HSP90 inhibition provides a therapeutic solution to the challenge of heterogeneous imatinib resistance mutations in GIST patients...
  50. ncbi Liposarcoma subtypes: identification with computed tomography and ultrasound-guided percutaneous needle biopsy
    Paul Nikolaidis
    Department of Radiology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Eur Radiol 15:383-9. 2005
    ..Although these data cannot be extrapolated to primary diagnosis of liposarcoma, they are important for screening and subtyping of possible recurrence...
  51. ncbi Recombinant human erythropoietin in cancer-related anemia: an evidence-based review
    Jayesh Desai
    Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Shields-Warren Building Room 530, 44 Binney Street, Boston, MA 02115, USA
    Best Pract Res Clin Haematol 18:389-406. 2005
    ....
  52. ncbi Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate
    Sridhar Shankar
    Department of Radiology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Mass, USA
    Radiology 235:892-8. 2005
    ..To investigate a new pattern of tumor recurrence observed at imaging in patients with metastatic gastrointestinal stromal tumor (GIST) after initial partial response to imatinib mesylate...
  53. ncbi Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification
    Katherine A Janeway
    Department of Pediatric Hematology Oncology, Dana Farber Cancer Institute and Children s Hospital, Boston, MA 02115, USA
    Int J Cancer 127:2718-22. 2010
    ..Despite the absence of apparent genomic activation mechanisms accounting for overexpression, clinical study of IGF1R-directed therapies in pediatric WT GIST is warranted...
  54. ncbi Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs)
    Anette Duensing
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Oncogene 23:3999-4006. 2004
    ....
  55. ncbi Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study
    R Garcia-Carbonero
    Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney St, Boston, Massachusetts 02115, USA
    J Clin Oncol 23:5484-92. 2005
    ....
  56. ncbi Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor
    James E Butrynski
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 363:1727-33. 2010
    ..Funded by Pfizer and others; ClinicalTrials.gov number, NCT00585195.)...
  57. ncbi Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
    S George
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Eur J Cancer 45:1959-68. 2009
    ....
  58. ncbi High-throughput oncogene mutation profiling in human cancer
    Roman K Thomas
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, Massachusetts 02115, USA
    Nat Genet 39:347-51. 2007
    ..These results offer a new dimension in tumor genetics, where mutations involving multiple cancer genes may be interrogated simultaneously and in 'real time' to guide cancer classification and rational therapeutic intervention...
  59. ncbi KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance
    M J Zhu
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Oncogene 26:6386-95. 2007
    ....
  60. ncbi KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway
    S Bauer
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02155, USA
    Oncogene 26:7560-8. 2007
    ..Targeting critical downstream signaling proteins, such as PI3-K, is a promising therapeutic strategy in imatinib-resistant GISTs...
  61. ncbi A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
    Zhao Chen
    Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nature 483:613-7. 2012
    ....
  62. ncbi Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genes
    Andre M Oliveira
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Oncogene 24:3419-26. 2005
    ..In summary, these studies show that USP6 oncogenic activation results from heterogeneous genomic mechanisms involving USP6 transcriptional upregulation by juxtaposition with ectopic promoters...
  63. ncbi Aberrant AKT activation drives well-differentiated liposarcoma
    Alejandro Gutierrez
    Department of Pediatric Oncology, The Dana Farber Cancer Institute, MA 02215, USA
    Proc Natl Acad Sci U S A 108:16386-91. 2011
    ..Our findings are unique in providing an animal model to decipher the molecular pathogenesis of WDLPS, and implicate AKT as a previously unexplored therapeutic target in this chemoresistant sarcoma...
  64. ncbi Update on new diagnostic and therapeutic approaches for sarcomas
    Palma Dileo
    Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Clin Adv Hematol Oncol 3:781-91. 2005
    ..The aim of this review is to provide a brief overview of the epidemiology, pathology, clinical presentation, and new approaches to the treatment of adult soft-tissue and bone sarcomas...
  65. ncbi Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations
    Katherine A Janeway
    Department of Pediatric Hematology Oncology, Dana Farber Cancer Institute and Children s Hospital, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 108:314-8. 2011
    ..Testing for germline mutations in SDH is recommended in patients with WT GIST. These findings highlight a potential central role of SDH dysregulation in WT GIST oncogenesis...
  66. ncbi Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
    Tammy F Chu
    Department of Cardiology, Children s Hospital Boston and Harvard Medical School, Boston, MA 02115, USA
    Lancet 370:2011-9. 2007
    ..We therefore assessed the cardiovascular risk associated with sunitinib in patients with metastatic gastrointestinal stromal tumours...
  67. ncbi Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial
    Andrew J Wagner
    Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 118:5894-902. 2012
    ..This study assessed the activity of tivantinib (ARQ 197), a selective MET inhibitor, in patients with MiT-associated tumors...
  68. ncbi Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options
    G D Demetri
    Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Semin Oncol 28:19-26. 2001
    ....
  69. ncbi Heterogeneity of kinase inhibitor resistance mechanisms in GIST
    B Liegl
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    J Pathol 216:64-74. 2008
    ..Our observations underscore the heterogeneity of clinical TKI resistance, and highlight the therapeutic challenges involved in salvaging patients after clinical progression on TKI monotherapies...
  70. ncbi Challenges in the development of platelet growth factors: low expectations for low counts
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Curr Hematol Rep 1:110-8. 2002
    ....
  71. ncbi Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas
    Danan Li
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Clin Invest 117:346-52. 2007
    ..Taken together, these data support the hypothesis that mAb806 may lead to significant advancements in the treatment of the population of NSCLC patients with these 2 classes of EGFR mutations...
  72. ncbi KIT activation is a ubiquitous feature of gastrointestinal stromal tumors
    B P Rubin
    Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA
    Cancer Res 61:8118-21. 2001
    ..These studies underscore the role of KIT activation in GIST pathogenesis, and they suggest that activated KIT might represent a universal therapeutic target in GISTs...
  73. ncbi Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy
    G D Demetri
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Br J Cancer 84:31-7. 2001
    ..With this new option for therapy, further avenues of investigation should lead to renewed interest in the clinical benefits of optimal haemoglobin levels for patients with cancer...
  74. ncbi Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group
    G D Demetri
    Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 16:3412-25. 1998
    ..To evaluate prospectively the effectiveness of epoetin alfa as an adjunct to chemotherapy in patients with cancer based on changes in quality-of-life parameters and hemoglobin levels, and to correlate these changes with antitumor response...
  75. ncbi Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma
    N F Esnaola
    Division of Surgical Oncology, Department of Surgery, Radiation Oncology and Pathology, Brigham and Women's Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Ann Surg 234:215-23. 2001
    ..Future systemic therapies should be targeted to patients with localized/locoregional disease and partial responders to conventional chemotherapy...
  76. ncbi The biology of GM-CSF: regulation of production and interaction with its receptor
    J D Griffin
    Division of Tumor Immunology, Dana Farber Cancer Institute, Boston, Massachusetts 02115
    Int J Cell Cloning 8:35-44; discussion 44-5. 1990
    ..Signal transduction involves activation of a tyrosine kinase and possibly G protein-coupled stimulation of Na+/H+ exchange. The exact relationship of the two receptors needs further clarification...
  77. ncbi GIST 1, chemotherapy 0, with a brand new hitter up next
    George D Demetri
    Cancer Invest 20:853-4. 2002
  78. ncbi Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases
    Michael C Heinrich
    Department of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute and Portland VA Medical Center, Portland, Oregon 97239 3098, USA
    Clin Cancer Res 14:2717-25. 2008
    ..To evaluate the activity of imatinib in treating advanced, life-threatening malignancies expressing one or more imatinib-sensitive tyrosine kinases...
  79. ncbi Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225
    Grant A McArthur
    Peter MacCallum Cancer Centre, East Melbourne, Australia
    J Clin Oncol 23:866-73. 2005
    ..The purpose of this study was to evaluate molecular, cytogenetic, and kinase activation profiles in a series of DFSPs and to determine whether these biologic parameters are correlated with the clinical responses of DFSP to imatinib...
  80. ncbi Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib
    Petri Bono
    Department of Oncology, University Central Hospital of Helsinki, Helsinki, Finland
    Blood 103:2929-35. 2004
    ..1-259-fold). A high serum SCF/KIT ratio may increase SCF-induced cell signaling with prolonged imatinib treatment, at the time when imatinib treatment is withdrawn, and in patients whose GIST has wild-type receptors...
  81. ncbi Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
    Michael C Heinrich
    R and D 19 3710 SW US Veterans Hospital Rd, Portland, OR 97207, USA
    J Clin Oncol 21:4342-9. 2003
    ..The relationship between mutations in these kinases and clinical response to imatinib was examined in a group of patients with advanced GIST...
  82. ncbi OncoloGIST, BioloGIST, RadioloGIST: the big impact on the field of oncology of a molecularly-targeted therapy designed to treat a rare disease
    George D Demetri
    Eur J Cancer 39:1976-7. 2003
  83. ncbi Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma
    Caroline Laverdiere
    Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Cancer 98:832-40. 2003
    ..CONCLUSIONS: ET-743 was found to be well tolerated in heavily pretreated osteosarcoma patients but had limited antitumor activity as a single agent. The combination of ET-743 with cisplatin or doxorubicin should be considered...
  84. ncbi Soft tissue sarcomas of adults: state of the translational science
    Ernest C Borden
    The Cleveland Clinic Foundation, Cleveland, Ohio, 44195, USA
    Clin Cancer Res 9:1941-56. 2003
    ..Finally, multicenter, coordinated trials, such as those that occurred with assessment of imatinib mesylate in metastatic gastrointestinal stromal tumors, will assure the most rapid reductions in morbidity and mortality...
  85. ncbi Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer
    Francisco J Esteva
    University of Texas M D Anderson Cancer Center, and Baylor College of Medicine, Houston, Texas 77030, USA
    J Clin Oncol 21:999-1006. 2003
    ..However, it is an oral agent with minimal toxicity and a unique mechanism of action, which produced clinical benefit in approximately 20% of patients. Future efforts should define populations likely to benefit from this agent...
  86. ncbi PDGFRA activating mutations in gastrointestinal stromal tumors
    Michael C Heinrich
    Department of Medicine, Department of Pathology, Oregon Health and Science University Cancer Institute and Portland VA Medical Center, Portland, OR 97201, USA
    Science 299:708-10. 2003
    ..Thus, KIT and PDGFRA mutations appear to be alternative and mutually exclusive oncogenic mechanisms in GISTs...
  87. ncbi Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy
    Jeffrey Crawford
    Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 95:888-95. 2002
    ..These data suggest that the maximal incremental gain in QOL occurs when hemoglobin is in the range of 11-13 g/dL...
  88. ncbi Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials
    John Glaspy
    University of California Los Angeles, Los Angeles, California, USA
    Oncologist 7:126-35. 2002
    ....
  89. ncbi Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel
    Deborah Toppmeyer
    Cancer Institute of New Jersey, New Brunswick, New Jersey 08903, USA
    Clin Cancer Res 8:670-8. 2002
    ..The safety and pharmacokinetics of the VX-710/pacitaxel regimen support further evaluation in breast cancer patients with initial paclitaxel therapy to prevent emergence of the MDR phenotype in recurrent disease...
  90. ncbi Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668
    Darren W Davis
    Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 11:678-89. 2005
    ..CONCLUSIONS: SU5416 and SU6668 displayed biological activity in xenografts. However, neither drug produced marked biological activity in primary patient tumors...
  91. ncbi Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors
    Jeanne M Griffin
    Clin J Oncol Nurs 9:161-9. 2005
    ..This article--based on published trials and clinical experience--summarizes the nursing implications, clinical efficacy, and safety of imatinib as an effective and rationally targeted treatment for GIST...
  92. ncbi A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib
    Tejas V Patel
    J Natl Cancer Inst 100:282-4. 2008
  93. ncbi Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
    Charles D Blanke
    Oregon Health and Science University Cancer Institute, 3181 SW Sam Jackson Park Rd, L 586, Portland, OR 97239, USA
    J Clin Oncol 26:626-32. 2008
    ....
  94. ncbi Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT
    Charles D Blanke
    Oregon Health and Science University Cancer Center and Portland Veterans Affairs Hospital, Portland, OR, USA
    J Clin Oncol 26:620-5. 2008
    ..We conducted a long-term analysis of patients treated on the trial, including patients followed during an extension phase, to evaluate survival, patterns of failure, and potential prognostic factors, including tumor mutational status...
  95. ncbi CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor
    Clay H Holdsworth
    Massachusetts College of Pharmacy and Health Sciences, 4 Brook Rd, Unit 11, Salem, NH 03079, USA
    AJR Am J Roentgenol 189:W324-30. 2007
    ....
  96. ncbi NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines
    George D Demetri
    J Natl Compr Canc Netw 5:S1-29; quiz S30. 2007
    ....
  97. ncbi Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study
    Federica Grosso
    Cancer Medicine Department, Adult Sarcoma Medical Treatment Unit, IRCCS Foundation National Cancer Institute, Milan, Italy
    Lancet Oncol 8:595-602. 2007
    ....
  98. ncbi Molecular correlates of imatinib resistance in gastrointestinal stromal tumors
    Michael C Heinrich
    Division of Hematology Oncology, Department of Pathology, Oregon Health and Science University Cancer Institute, Oregon Health and Science University, Portland, OR, USA
    J Clin Oncol 24:4764-74. 2006
    ..In clinical studies, 75% to 90% of patients with advanced GISTs experience clinical benefit from imatinib. However, imatinib resistance is an increasing clinical problem...
  99. ncbi Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor)
    Michael C Heinrich
    Oregon Health and Science University Cancer Institute and Portland VA Medical Center, Portland, OR, USA
    J Clin Oncol 24:1195-203. 2006
    ..To determine the clinical efficacy of imatinib in patients with advanced aggressive fibromatosis (AF) and to identify the molecular basis of response/nonresponse to this agent...
  100. ncbi Cancer- and treatment-related anemia
    George M Rodgers
    J Natl Compr Canc Netw 3:772-89. 2005
  101. ncbi Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma
    Vivien H C Bramwell
    Department of Medical Oncology, London Regional Cancer Centre, 790 Commissioners Road, London, Ontario, Canada N6A 4L6
    Clin Cancer Res 8:383-93. 2002
    ..However, the combination of VX-710 and doxorubicin resulted in objective responses or disease stabilization in patients with strictly defined anthracycline-refractory non-GIST sarcomas, which warrants further evaluation...